Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18295978 | 0.86 | NR1H2 (0.57) | NR1H2KITFAAHACHESRC | |
| SCHEMBL20142109 | 0.83 | MAPT (0.52) | GAAKITKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL22987187 | 0.80 | NR1H2 (0.61) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL2708121 | 0.80 | NR1H2 (0.67) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL17134920 | 0.80 | NR1H2 (0.75) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL20214542 | 0.78 | NR1H2 (0.58) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL24192760 | 0.78 | NR1H2 (0.77) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL29959027 | 0.78 | NR1H2 (0.77) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL24192421 | 0.78 | NR1H2 (0.77) | NR1H2GAAKITKDM4EALDH1A1 | |
| SCHEMBL4678727 | 0.78 | EPHX2 (0.48) | NR1H2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10925868-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| WO-2018089736-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10925868-B2 | Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use | MDM2, DSTYK, MAP2K2 | NR1H2 2864/4885GAA 1692/4885KIT 926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.